Multiple MyelomaiPREFERNCT06322927
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
An observational study of Multiple Myeloma, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Patient Interview
- How many people
- 9 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Apr 2024to 30 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with multiple myeloma who have received at least five lines of treatment.
Who may be able to join
- Participants with confirmed MM (per standard disease specific diagnostic criteria)
- Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
- Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
- Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
- Aged 18 years of age or over
- Able to provide informed consent
- Able to communicate in English
Who cannot join
- Aged under 18
- Unable to understand and communicate in the English language
- Unable to provide written informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
The Christie NHS Foundation Trust
Manchester, Greater Manchester, M20 4BX
About this study
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Read the detailed description
People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.
- Conditions
- Multiple Myeloma
- Being tested
- Patient Interview
- Keywords
- Patient Experience, Treatment Preference, Qualitative Study, Patient Interviews
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient InterviewOther
Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
| Study group | Role | What they receive |
|---|---|---|
| Patient Interviews | Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference. Receives: Other: Patient Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Experience and Preference
The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
Measured: 30-60 minutes
Secondary outcomes (1)
Treatment and Preference Differences
The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments.
Measured: 30-60 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2024
- Study start5 Apr 2024
- Primary completion30 Sep 2024
- Study completion30 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Christie NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- CellCentric Ltd.
- Responsible party
- Sponsor
- Investigators
- Sally Taylor, PhD, Principal investigator, The Christie NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06322927
- Sponsor's protocol ID
- CFTsp231
- Other IDs
- 24_CPCR_38
- Acronym
- iPREFER
- Status last verified
- May 2026
- First submitted
- 14 Mar 2024
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Perry MB, Lochhead Devaraj R, Law K, Ashby F, Taylor S. iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study. Patient Prefer Adherence. 2026 Apr 28;20:576524. doi: 10.2147/PPA.S576524. eCollection 2026.
PubMed 42080199
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
- ClinicalTrials.gov ID
- NCT06322927
- Acronym / sponsor ID
- iPREFER / CFTsp231
- Conditions
- Multiple Myeloma
- Keywords
- Patient Experience, Treatment Preference, Qualitative Study, Patient Interviews
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- The Christie NHS Foundation TrustUniversity, hospital or other
- Collaborators
- CellCentric Ltd.
- Study start
- 5 Apr 2024 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 30 Sep 2024 (actual)
- First posted
- 21 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Detailed description
People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient Interviews | – | Other: Patient InterviewParticipants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with multiple myeloma who have received at least five lines of treatment.
Key inclusion criteria (7 listed)
- Participants with confirmed MM (per standard disease specific diagnostic criteria)
- Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
- Aged 18 years of age or over
- Able to provide informed consent
- Able to communicate in English
Key exclusion criteria (3 listed)
- Aged under 18
- Unable to understand and communicate in the English language
- Unable to provide written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient InterviewParticipants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences. | Other | Patient Interviews |
Primary outcome
Patient Experience and Preference
Time frame: 30-60 minutes
The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
1 secondary outcome
Treatment and Preference Differences
Time frame: 30-60 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Derived from this study: PubMed 42080199Perry MB, Lochhead Devaraj R, Law K, Ashby F, Taylor S. iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study. Patient Prefer Adherence. 2026 Apr 28;20:576524. doi: 10.2147/PPA.S576524. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Myeloma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sally Taylor, PhD principal investigator
The Christie NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Myeloma, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Experience and Preference (time frame: 30-60 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06322927, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.